Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF
Open Access
- 18 September 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 7 (18) , e008928
Abstract
Background: Chronic kidney disease ( CKD ) is a common comorbidity in patients with atrial fibrillation. The presence of CKD complicates drug selection for stroke prevention and rhythm control. Methods and Results: Patients enrolled in ORBIT AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) with baseline renal function and follow‐up data were included (N=9019). CKD was defined as an estimated creatinine clearance 2 DS 2 VAS c and Anticoagulant and Risk Factors in Atrial Fibrillation (ATRIA) scores. A rhythm control strategy was selected less frequently in patients with CKD , while OAC use was lower among Stage IV and V CKD patients. After adjustment, no significant interaction was noted for OAC and CKD on all‐cause mortality ( P =0.5442) or cardiovascular death ( P =0.1233), although a trend for increased major bleeding ( P =0.0608) and stroke, systemic embolism or transient ischemic attack ( P =0.0671) was observed. No interaction was noted for antiarrhythmic drug use and CKD status on all‐cause mortality ( P =0.9706), or stroke, systemic embolism or transient ischemic attack ( P =0.4218). Conclusions: Patients with atrial fibrillation and CKD are less likely to be treated with rhythm control. Patients with advanced CKD are less likely to receive OAC . Finally, outcomes with OAC in patients with advanced CKD may be materially different with higher rates of both bleeding and stroke.Keywords
This publication has 13 references indexed in Scilit:
- Morbidity and treatment in patients with atrial fibrillation and chronic kidney diseaseKidney International, 2015
- Warfarin Use and the Risk for Stroke and Bleeding in Patients With Atrial Fibrillation Undergoing DialysisCirculation, 2014
- Edoxaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2013
- Rate versus rhythm control for management of atrial fibrillation in clinical practice: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryAmerican Heart Journal, 2013
- Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AFAmerican Heart Journal, 2011
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- A Comparison of Rate Control and Rhythm Control in Patients with Recurrent Persistent Atrial FibrillationNew England Journal of Medicine, 2002
- A Comparison of Rate Control and Rhythm Control in Patients with Atrial FibrillationNew England Journal of Medicine, 2002